Lorlatinib is licensed as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on
(i) alectinib or ceritinib as the first ALK-targeted treatment, or
(ii) crizotinib and at least one other ALK-targeted treatment.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||30/04/2019|
|Rapid review completed||25/06/2019|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that lorlatinib not be considered for reimbursement at the submitted price. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.|
The HSE has approved reimbursement following confidential price negotiations (October 2019).